TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06482827

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive transcranial magnetic stimulation
Description: Sham repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. During the sham, participants will hear and experience the clicking from the device but will not be provided with any stimulation. The delivery of sham rTMS requires \~ 11.5 minutes in total.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 2004 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of rTMS requires \~ 11.5 minutes in total.
Study: NCT04294940

Intervention type: OTHER
Group type: OTHER
Intervention: Wear an actigraph
Description: Between visits, tha patient will have to:~* Follow the hygiene-dietetic recommendations given by their centre.~* Wear the actigraph night and day Patients

Intervention type: OTHER
Group type: OTHER
Intervention: Use the mobile application CardiCare™ and wear an actigraph
Description: Between visits, tha patient will have to:~* Follow the hygiene-dietetic recommendations given by their centre.~* Wear the actigraph night and day Patients~* wear their smartphone everyday and use the mobile application CardiCare™
Study: NCT05218941

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant surgery assisted by passive robotics
Description: Implant surgery without flap assisted by passive robotics (X-Guide®)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional implant surgery
Description: Flap implant surgery
Study: NCT05582356

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate group (Group OC)
Description: Carbohydrate group (Group OC)

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Placebo group (Group OP
Description: Placebo group (Group OP
Study: NCT04796272

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted and individualized physical training program
Description: Physical training program adapted and individualized according to each patient in this group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional training program
Description: Same training program for all patients in this group
Study: NCT05800353

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: YAG vitreolysis
Description: A Karickoff lens with goniosol will be used to perform the YAG vitreolysis. The number of shots will be determined at the discretion of the treating physician. A focus offset may be used at investigator discretion. Single shot mode will be used. The maximum energy per pulse will be 7 mJ. The endpoint of treatment is the vaporization of the Weiss ring into gas, as well as the disruption of it into smaller fragments as well as any other vitreous opacities deemed visually significant by the treating physician.~Sham laser treatment will be applied under the same procedure used for laser treatment but by turning the laser power down to 0.3 mJ and using a separate lens covered by a filter that absorbs the power, so no laser enters the eye.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: YAG vitreolysis
Description: A Karickoff lens with goniosol will be used to perform the YAG vitreolysis. The number of shots will be determined at the discretion of the treating physician. A focus offset may be used at investigator discretion. Single shot mode will be used. The maximum energy per pulse will be 7 mJ. The endpoint of treatment is the vaporization of the Weiss ring into gas, as well as the disruption of it into smaller fragments as well as any other vitreous opacities deemed visually significant by the treating physician.~Sham laser treatment will be applied under the same procedure used for laser treatment but by turning the laser power down to 0.3 mJ and using a separate lens covered by a filter that absorbs the power, so no laser enters the eye.
Study: NCT04839250

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: heads-up method
Description: 3D surgical video system, which includes Alcon NGENUITY 3D visualization system (Alcon, Fort Worth, TX) and Leica M822 and M844 microscopes (Leica Microsystems, Wetzlar, Germany),can be used to perform head-up phacoemulsification combined with intraocular lens implantation surgery.
Study: NCT05640050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audit Implementation
Description: The feasibility of establishing and implementing an acceptable and robust audit system with community representation at secondary health facilities to improve maternal and perinatal outcomes. The implementation phases follow the standard World Health Organization (WHO) audit system.
Study: NCT06068946

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VK2735
Description: VK2735 is a peptide GLP-1 and GIP dual agonist

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VK2735
Description: VK2735 is a peptide GLP-1 and GIP dual agonist

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VK2735
Description: VK2735 is a peptide GLP-1 and GIP dual agonist

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VK2735
Description: VK2735 is a peptide GLP-1 and GIP dual agonist

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT05404191

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: Low level laser therapy will be performed for 30 min 3 times per week for 8 weeks on the wound area.~Wound area was irradiated by a red 655 nm light, 150 mW, 2 J/cm2 at the bed of the wound.
Study: NCT05733741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative-free Benoxinate hydrochloride 0.4% (Benoxidia unit-dose vials [UD], Orchidia pharmaceutical Ind., Egypt)
Description: For each patient, one eye was treated with preservative-free Benoxinate hydrochloride 0.4%.~The prescribed regimen comprises of the instillation of one drop immediately, 2, 4, 6 and 8 hours after the end of surgery.~Every patient was given 5 UD vials only of preservative-free Benoxinate hydrochloride 0.4% at each follow up visit for the next postoperative day usage administered 5 times daily (every 3 hours while awake) for the first 3 postoperative days giving clear instructions to immediately discard the vial after single use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Preservative-free Sodium hyaluronate 0.2% (Polyfresh unit-dose vials [UD], Orchidia pharmaceutical Ind., Egypt).
Description: The other eye was treated with preservative-free Sodium hyaluronate 0.2%. The prescribed regimen comprises of the instillation of one drop immediately, 2, 4, 6 and 8 hours after the end of surgery.~Every patient was given 5 UD vials only of preservative-free Sodium hyaluronate 0.2% at each follow up visit for the next postoperative day usage administered 5 times daily (every 3 hours while awake) for the first 3 postoperative days giving clear instructions to immediately discard the vial after single use.
Study: NCT05989672

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSVTI Formulation 1
Description: This investigational intervention will be administered intramuscular as 2 doses to HSVTI_F1 Group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSVTI Formulation 2
Description: This investigational intervention will be administered intramuscular as 2 doses to HSVTI_F2 Group.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This intervention will be administered intramuscular as 2 doses to Placebo group.
Study: NCT06279117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: therapeutic touch
Description: Individuals who undergo therapeutic touch will receive therapeutic touch for 20 minutes 30 minutes before the exam.
Study: NCT04678661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone application and web portal
Description: My Dose Coach is indicated for single patient use outside the clinic setting by a previously diagnosed Type 2 Diabetic who has been prescribed a once-daily long-acting basal insulin. MDC is intended as an aid to the patient to provide dose suggestions based upon the HCP's independent professional judgment. Before My Dose Coach can be used, the HCP configures the dose instructions for the specific patient and activates the application using the specific patient Instructions. The application uses the dose plan instructions provided by the patient's HCP to provide dose suggestions of once-daily long-acting basal insulin (i.e. basal insulin titration) that are based on the patient's Fasting Blood Glucose (FBG) as well as hypoglycemia occurrence.~MDC includes a Maintenance Module designed to support patients in maintaining proper insulin dosingby enabling logging of administered doses of prescribed diabetes medications and BGM and providing dosing and measurement reminders.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Insulin Therapy Education
Description: Standard best practices for training patients to administer insulin therapy include 1) a thorough patient assessment prior to therapy initiation to address barriers, including evaluation for diminished cognitive capacity or other problem that may impair safe insulin self-administration, and assessment of health literacy and numeracy skills; 2) observation of a patient's injection practice, with re-education provided as needed; 3) use of appropriate language is necessary when teaching injection technique; 4) dose preparation, which includes inspecting the insulin dose for accuracy (following manufacturer instructions); and 5) review of signs, symptoms and treatment of hypoglycemia must be included as a critical component of the training.
Study: NCT04888026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quantitative sensory testing
Description: The following QSTs are conducted:~The pressure pain threshold on the tibialis anterior~The Cold-pressor test~Repeat of the pressure pain threshold to assess conditioned pain modulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative sensory testing
Description: The following QSTs are conducted:~The pressure pain threshold on the tibialis anterior~The Cold-pressor test~Repeat of the pressure pain threshold to assess conditioned pain modulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative sensory testing
Description: The following QSTs are conducted:~The pressure pain threshold on the tibialis anterior~The Cold-pressor test~Repeat of the pressure pain threshold to assess conditioned pain modulation
Study: NCT06370624

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI-scan
Description: IRM-scan at rest under neonatologist monitoring.
Study: NCT05183516

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine
Description: Tdap is a combination vaccine that protects against three potentially life-threatening bacterial diseases: tetanus, diphtheria, and pertussis (whooping cough).
Study: NCT04593186

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans-oral magnifying endoscopy with NBI
Description: Endoscopic procedures would be performed by endoscopists with expertise on performing magnifying NBI endoscopy. Topical local anaesthetic will be applied to the oropharynx and nasopharynx. In addition, intravenous sedation by use of Midazolam and Fentanyl would be given. Endoscopes with magnification and NBI function would be used (GF-H290Z, Olympus Medical Corporations, Tokyo, Japan). A soft black hood would be attached to the tip of the endoscope for better focal length adjustment.~Upon insertion through a mouthpiece, the scope will then be retroflexed into the nasopharynx and the lateral walls into the Fossa of Rosenmuller and the posterior nasopharyngeal wall will be systematically examined with white light and NBI. Target suspicious areas would be examined by use of magnification with the power up to 80X. Biopsy would be taken if suspicious lesion is identified during the procedure.
Study: NCT05777785

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIZO Glasses
Description: Eyeglasses with personalized peripheral retinal stimuli
Study: NCT05054491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Antenatal Care
Description: Group ANC is an integrated approach that incorporates physical assessment, education and skill development, and peer support and takes a broader, more holistic, woman-centered approach to traditional antenatal care
Study: NCT05529082

Intervention type: OTHER
Intervention: Opioid Attitudes
Description: Participants will complete a questionnaire about your feelings/beliefs on prescription pain medication and your experience with opioids/pain medication. Demographic information about you (such as your age, gender, race, ethnicity, and so on) will also be collected.

Intervention type: OTHER
Intervention: Beliefs survey
Description: Participants will complete a questionnaire about your feelings/beliefs on prescription pain medication and your experience with opioids/pain medication. Demographic information about you (such as your age, gender, race, ethnicity, and so on) will also be collected.
Study: NCT06374888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib maleate in combination with capecitabine
Description: Neratinib maleate tablets，Tablets, 40mg/ tablet, 180 tablets/bottle, orally, 240mg once daily, sealed, stored not above 25℃
Study: NCT05226832

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 40mg Triamcinolone Injections in the Bladder
Description: Patients will undergo a standard of care cystoscopy with non-standard of care solumedrol injections in the clinic. Subjects will have lidocaine jelly instilled into their bladder for 5 minutes prior to injection cystoscopy. Injections will be performed using a 17fr flexible cystoscope in the outpatient setting. There will be 10 intravesical Injections of 1cc of 40mg solumedrol diluted to 10cc with injectable normal saline. The needle will penetrate the bladder at a depth of 2-3mm using a Laborie endoscopic single use needle, about the length of a pencil tip. The patient may experience discomfort with cystoscopy and injections. Any procedure complications will be noted based on the Clavien-Dindo Classification Index, discussed in the safety section. This is estimated to take 30 minutes.
Study: NCT04898348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBL697
Description: 3 capsules twice a day dosing of KBL697

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 capsules twice a day dosing of Placebo
Study: NCT05477446

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD207 CAR-T cells
Description: Single dose of CD207 CAR-T cells administered IV
Study: NCT04799457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suture technique
Description: We wil apply additional sutures to classical caesarean procedure.
Study: NCT04894019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous invasive blood pressure monitoring
Description: Continuous invasive blood pressure monitoring using an arterial catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent non-invasive blood pressure monitoring
Description: Intermittent non-invasive blood pressure monitoring using upper-arm cuff oscillometry
Study: NCT04678661

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Insulin Therapy Education
Description: Standard best practices for training patients to administer insulin therapy include 1) a thorough patient assessment prior to therapy initiation to address barriers, including evaluation for diminished cognitive capacity or other problem that may impair safe insulin self-administration, and assessment of health literacy and numeracy skills; 2) observation of a patient's injection practice, with re-education provided as needed; 3) use of appropriate language is necessary when teaching injection technique; 4) dose preparation, which includes inspecting the insulin dose for accuracy (following manufacturer instructions); and 5) review of signs, symptoms and treatment of hypoglycemia must be included as a critical component of the training.
Study: NCT06239324

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: Comparing between Erbium YAG laser assisted drug delivery of latanoprost versus transepidermal latanoprost delivery by microneedling in alopecia areata treatment for all participants.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: Comparing between Erbium YAG laser assisted drug delivery of latanoprost versus transepidermal latanoprost delivery by microneedling in alopecia areata treatment for all participants.
Study: NCT05685719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI-1558
Description: An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI-1558
Description: An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI-1558
Description: An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI-1558
Description: An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).
Study: NCT06139614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PERSIST
Description: PERSIST is adapted from empirically validated treatment of negative affect and low positive emotion. Skills Training 1 includes content across 4 sessions on 1) understanding emotions, 2) present-moment emotional awareness, 3) cognitive flexibility, and 4) countering avoidant and emotion-driven responses. Skills Training 2 includes content across 4 sessions on a) translating values to action, b) lower barriers to action, c) countering avoidance, and d) maintaining actions that support personal resilience. The classes will occur every other Wednesday, resulting in a 16-week intervention period.
Study: NCT05685719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: A strong CYP3A4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: A strong CYP3A4 inducer
Study: NCT06338007

Intervention type: DEVICE
Intervention: Hand Dynamometer
Description: Hand grip strength will be measured using a hand dynamometer. Research has demonstrated that hand grip strength is correlated with muscle strength in the upper extremities, as well as overall body and pulmonary muscle strength.

Intervention type: DEVICE
Intervention: Hand Dynamometer
Description: Hand grip strength will be measured using a hand dynamometer. Research has demonstrated that hand grip strength is correlated with muscle strength in the upper extremities, as well as overall body and pulmonary muscle strength.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function Test
Description: Spirometry is a physiological test that measures the ability to inhale and exhale air relative to time. Spirometry is a diagnostic test of several common respiratory disperses such as asthma and chronic obstructive pulmonary disease (COPD). It is also instrumental in monitoring the progression of various respiratory disorders. The main results of spirometry are forced vital capacity (FVC), forced expiratory volume exhaled in the first second (FEV1), and the FEV1/FVC ratio. Pulmonary Function Test analysis values (FEV1, FVC and FEV1 /FVC) will be used.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function Test
Description: Spirometry is a physiological test that measures the ability to inhale and exhale air relative to time. Spirometry is a diagnostic test of several common respiratory disperses such as asthma and chronic obstructive pulmonary disease (COPD). It is also instrumental in monitoring the progression of various respiratory disorders. The main results of spirometry are forced vital capacity (FVC), forced expiratory volume exhaled in the first second (FEV1), and the FEV1/FVC ratio. Pulmonary Function Test analysis values (FEV1, FVC and FEV1 /FVC) will be used.

Intervention type: OTHER
Intervention: Modified Frailty Index
Description: The modified frailty index is a valuable preoperative risk assessment tool that can be used to assess the risk of both morbidity and mortality in patients undergoing surgery. It is calculated based on 11 parameters.

Intervention type: OTHER
Intervention: Modified Frailty Index
Description: The modified frailty index is a valuable preoperative risk assessment tool that can be used to assess the risk of both morbidity and mortality in patients undergoing surgery. It is calculated based on 11 parameters.
Study: NCT05474755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP681 40mg
Description: 2X20mg tablets taken orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching GP681 40mg
Study: NCT04874844

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant anti-VEGFR2 fully human monoclonal antibody (JY025)
Description: The ratio of subjects in the experimental drug group to the placebo control group is 1:1, and you will have a 50% probability of receiving JY025 combined with gefitinib or erlotinib, and a 50% probability of receiving placebo combined with gefitinib Or erlotinib.~Blind people, researchers, nurses, research assistants, inspectors, applicants and blind statisticians involved in clinical trials.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Recombinant anti-VEGFR2 fully human monoclonal antibody (JY025)
Description: The ratio of subjects in the experimental drug group to the placebo control group is 1:1, and you will have a 50% probability of receiving JY025 combined with gefitinib or erlotinib, and a 50% probability of receiving placebo combined with gefitinib Or erlotinib.~Blind people, researchers, nurses, research assistants, inspectors, applicants and blind statisticians involved in clinical trials.
Study: NCT05073913

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Vascular remodeling characterization
Description: Pulse wave velocity measure High frequency ultrasonography for vascular imaging Endothelial function test Left ventricular mass by echocardiography Measurement of GFR (Glomerular Filtration Rate) with decrease in plasma of Iohexol

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Vascular remodeling characterization
Description: Pulse wave velocity measure High frequency ultrasonography for vascular imaging Endothelial function test Left ventricular mass by echocardiography Measurement of GFR (Glomerular Filtration Rate) with decrease in plasma of Iohexol